Clinical trialNCT04973228CompletedPhase 3Interventional

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

SponsorArcutis Biotherapeutics, Inc.Enrollment457Seborrheic Dermatitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

53 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Arcutis Biotherapeutics Clinical Site 35
Calgary, Alberta, Canada
Arcutis Biotherapeutics Clinical Site 37
Surrey, British Columbia, Canada
Arcutis Biotherapeutics Clinical Site 47
Winnipeg, Manitoba, Canada
Arcutis Biotherapeutics Clinical Site 43
Fredericton, New Brunswick, Canada
Arcutis Biotherapeutics Clinical Site 16
London, Ontario, Canada
Arcutis Biotherapeutics Clinical Site 29
Mississauga, Ontario, Canada
Arcutis Biotherapeutics Clinical Site 30
North Bay, Ontario, Canada
Arcutis Biotherapeutics Clinical Site 32
Peterborough, Ontario, Canada
Arcutis Biotherapeutics Clinical Site 36
Waterloo, Ontario, Canada
Arcutis Biotherapeutics Clinical Site 09
Westmount, Quebec, Canada

United States

Arcutis Biotherapeutics Clinical Site 01
Scottsdale, Arizona, United States
Arcutis Biotherapeutics Clinical Site 45
Encinitas, California, United States
Arcutis Biotherapeutics Clinical Site 46
San Diego, California, United States
Arcutis Biotherapeutics Clinical Site 64
San Diego, California, United States
Arcutis Biotherapeutics Clinical Site 21
Santa Monica, California, United States
Arcutis Biotherapeutics Clinical Site 42
Coral Gables, Florida, United States
Arcutis Biotherapeutics Clinical Site 57
Delray Beach, Florida, United States
Arcutis Biotherapeutics Clinical Site 33
Largo, Florida, United States
Arcutis Biotherapeutics Clinical Site 31
North Miami Beach, Florida, United States
Arcutis Biotherapeutics Clinical Site 65
Sanford, Florida, United States
Arcutis Biotherapeutics Clinical Site 12
Tampa, Florida, United States
Arcutis Biotherapeutics Clinical Site 10
Rolling Meadows, Illinois, United States
Arcutis Biotherapeutics Clinical Site 03
Indianapolis, Indiana, United States
Arcutis Biotherapeutics Clinical Site 22
Plainfield, Indiana, United States
Arcutis Biotherapeutics Clinical Site 15
Louisville, Kentucky, United States
Arcutis Biotherapeutics Clinical Site 04
Lake Charles, Louisiana, United States
Arcutis Biotherapeutics Clinical Site 02
Rockville, Maryland, United States
Arcutis Biotherapeutics Clinical Site 28
Rockville, Maryland, United States
Arcutis Biotherapeutics Clinical Site 40
Clinton Township, Michigan, United States
Arcutis Biotherapeutics Clinical Site 20
Detroit, Michigan, United States
Arcutis Biotherapeutics Clinical Site 14
Fridley, Minnesota, United States
Arcutis Biotherapeutics Clinical Site 44
Saint Joseph, Missouri, United States
Arcutis Biotherapeutics Clinical Site 19
Reno, Nevada, United States
Arcutis Biotherapeutics Clinical Site 34
East Windsor, New Jersey, United States
Arcutis Biotherapeutics Clinical Site 66
New York, New York, United States
Arcutis Biotherapeutics Clinical Site 63
The Bronx, New York, United States
Arcutis Biotherapeutics Clinical Site 23
High Point, North Carolina, United States
Arcutis Biotherapeutics Clinical Site 70
Winston-Salem, North Carolina, United States
Arcutis Biotherapeutics Clinical Site 18
Bexley, Ohio, United States
Arcutis Biotherapeutics Clinical Site 71
Portland, Oregon, United States

13 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Roflumilast FoamVehicle Foam

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Jul 2021
Primary completion: 6 Apr 2022
Completion: 6 Apr 2022
Last update posted: 12 Mar 2024
Registered enrollment: 457
Registry id: NCT04973228

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.